Chargement en cours...

非小细胞肺癌分子靶向治疗中EGFR-TKI的耐药机制研究进展

With a greater understanding of tumor biology, novel molecular-targeted strategies that block cancer progression pathways have been evaluated as a new therapeutic approach for treating non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Zhongguo Fei Ai Za Zhi
Format: Artigo
Langue:Inglês
Publié: 中国肺癌杂志编辑部 2012
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000259/
https://ncbi.nlm.nih.gov/pubmed/22336239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.08
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!